IL139701A0 - Enteric coated pharmaceutical tablet and method of manufacturing - Google Patents

Enteric coated pharmaceutical tablet and method of manufacturing

Info

Publication number
IL139701A0
IL139701A0 IL13970198A IL13970198A IL139701A0 IL 139701 A0 IL139701 A0 IL 139701A0 IL 13970198 A IL13970198 A IL 13970198A IL 13970198 A IL13970198 A IL 13970198A IL 139701 A0 IL139701 A0 IL 139701A0
Authority
IL
Israel
Prior art keywords
manufacturing
enteric coated
pharmaceutical tablet
coated pharmaceutical
tablet
Prior art date
Application number
IL13970198A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL139701A0 publication Critical patent/IL139701A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13970198A 1998-07-17 1998-08-06 Enteric coated pharmaceutical tablet and method of manufacturing IL139701A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11841898A 1998-07-17 1998-07-17
PCT/US1998/016323 WO2000003696A1 (en) 1998-07-17 1998-08-06 Enteric coated pharmaceutical tablet and method of manufacturing

Publications (1)

Publication Number Publication Date
IL139701A0 true IL139701A0 (en) 2002-02-10

Family

ID=22378467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13970198A IL139701A0 (en) 1998-07-17 1998-08-06 Enteric coated pharmaceutical tablet and method of manufacturing

Country Status (35)

Country Link
US (2) US6331316B1 (lt)
EP (1) EP1098635B1 (lt)
JP (1) JP2002520350A (lt)
KR (1) KR100535954B1 (lt)
CN (1) CN1195499C (lt)
AR (1) AR019934A1 (lt)
AT (1) ATE268165T1 (lt)
AU (1) AU750388B2 (lt)
BG (1) BG65443B1 (lt)
BR (1) BR9815948A (lt)
CA (1) CA2337885C (lt)
CO (1) CO5090840A1 (lt)
CZ (1) CZ301557B6 (lt)
DE (1) DE69824319T2 (lt)
DK (1) DK1098635T3 (lt)
EE (1) EE05021B1 (lt)
EG (1) EG23944A (lt)
ES (1) ES2221188T3 (lt)
GE (1) GEP20032912B (lt)
HU (1) HU226492B1 (lt)
ID (1) ID27019A (lt)
IL (1) IL139701A0 (lt)
LT (1) LT4844B (lt)
LV (1) LV12638B (lt)
NO (1) NO330554B1 (lt)
NZ (1) NZ508298A (lt)
PL (1) PL195587B1 (lt)
PT (1) PT1098635E (lt)
RO (1) RO121082B1 (lt)
RU (1) RU2201217C2 (lt)
SK (1) SK285152B6 (lt)
TR (1) TR200003577T2 (lt)
UA (1) UA73092C2 (lt)
WO (1) WO2000003696A1 (lt)
ZA (1) ZA993446B (lt)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6756811B2 (en) * 2000-03-10 2004-06-29 Easic Corporation Customizable and programmable cell array
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
WO2003026626A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US20030180356A1 (en) * 2001-10-29 2003-09-25 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
AU2003201735B2 (en) * 2002-01-11 2008-11-13 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
EP1476139B1 (en) * 2002-02-21 2017-05-17 Valeant Pharmaceuticals Luxembourg S.à.r.l. Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
MXPA05002095A (es) * 2002-09-03 2005-06-06 Biovail Lab Int Srl Formulaciones farmaceuticas de pravastatina y metodos de su uso.
CN1688293A (zh) * 2002-09-16 2005-10-26 韦思公司 多肽治疗剂口服给药的缓释配方及其使用方法
US8685445B2 (en) 2002-10-01 2014-04-01 Banner Pharmacaps Inc. Enteric composition for the manufacture of soft capsule wall
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
AU2004311849B2 (en) * 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US20090281067A1 (en) 2004-01-30 2009-11-12 The John Hopkins University Nitroxyl progenitor compounds and methods of use
US20100183714A1 (en) * 2004-03-26 2010-07-22 Lek Pharmaceuticals D.D. Gastroresistant pharmaceutical dosage form comprising n-(2-(2- phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
RU2276974C2 (ru) * 2004-07-01 2006-05-27 Некоммерческое партнерство Научно-технический центр "Лекарства и биотехнология" (НТЦ "Лекбиотех") Лекарственное средство "гастропек" для улучшения процессов пищеварения и способ его применения
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
TW200631609A (en) * 2004-11-18 2006-09-16 Bristol Myers Squibb Co Enteric coated bead comprising ixabepilone, and preparation and administration thereof
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CN100398122C (zh) * 2005-01-28 2008-07-02 北京北大药业有限公司 一种治疗颈、腰椎病中药的肠溶包衣组合物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
PL1916995T5 (pl) 2005-07-29 2022-10-31 Stichting Groningen Centre For Drug Research Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2617150C (en) * 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
ES2388310T7 (es) 2006-01-27 2017-05-03 The Regents Of The University Of California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
BRPI0708804B8 (pt) 2006-03-17 2021-05-25 Cardioxyl Pharmaceuticals Inc compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit
WO2008015686A1 (en) * 2006-08-01 2008-02-07 Hetero Drugs Limited Stable multiparticulate formulations of didanosine
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
SG185255A1 (en) 2007-09-26 2012-11-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
WO2009070781A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
JP5654450B2 (ja) 2008-05-07 2015-01-14 カルディオキシル ファーマシューティカルズ，インク． ニトロキシル供与体としての新規ニトロソ化合物およびその使用方法
US20090317466A1 (en) * 2008-06-18 2009-12-24 Franco Lori Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
BRPI0914305B8 (pt) 2008-06-19 2021-05-25 Xcovery Holding Co Llc compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
WO2010042163A2 (en) 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
CA2752800C (en) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2405898A2 (en) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US8513261B2 (en) * 2009-03-13 2013-08-20 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
MX356796B (es) * 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
CN105919987B (zh) 2009-12-07 2020-04-03 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物及其用途
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
PL2625176T3 (pl) 2010-10-08 2017-08-31 Xcovery Holding Company Llc Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
WO2013049731A1 (en) * 2011-09-30 2013-04-04 Stomavite Llc A supplement for ostomy patients
AU2013201929B2 (en) 2011-10-17 2015-07-23 The Johns Hopkins University N-substituted hydroxylamine derivatives with carbon-based leaving groups
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
CN102526746B (zh) * 2012-02-04 2013-09-18 安徽山河药用辅料股份有限公司 肠溶型水分散体包衣材料的制备方法
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
TWI619491B (zh) 2013-01-18 2018-04-01 卡爾迪奧克斯爾製藥公司 包含硝醯基予體的醫藥組合物
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
WO2015195989A1 (en) 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016106135A1 (en) 2014-12-23 2016-06-30 Cerecor, Inc. Compounds, compositions and methods
RU2668499C2 (ru) * 2015-03-12 2018-10-01 Закрытое Акционерное Общество "Фармфирма "Сотекс" Фармацевтическая композиция в форме таблеток, покрытых кишечнорастворимой оболочкой, и способ ее получения
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
BR112017025742A2 (pt) 2015-06-09 2018-08-07 Rexahn Pharmaceuticals, Inc. métodos de uso de fluorciclopentanilcitosina
JP2018526392A (ja) 2015-09-04 2018-09-13 レクサン ファーマシューティカルズ インコーポレイテッド キノキサリニル−ピペラジンアミドの使用方法
EP3370748B1 (en) 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
WO2017087532A1 (en) 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2017191501A2 (en) 2016-05-04 2017-11-09 D'oosterlynck André Simmondsin formulation
CN108366994B (zh) 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
BR112020022294A2 (pt) 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020096992A1 (en) 2018-11-05 2020-05-14 MarvelBiome, Inc. Microbial compositions comprising ellagitannin and methods of use
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020212822A1 (en) * 2019-04-17 2020-10-22 Amruth Gowda Doddaveerappa Multi-component pharmaceutical single dosage forms and process employed thereof
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
CN110882228A (zh) * 2019-11-29 2020-03-17 南京禾瀚医药科技有限公司 一种伊匹乌肽肠溶制剂
WO2021115650A1 (en) * 2019-12-11 2021-06-17 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
EP4158014A2 (en) 2020-05-26 2023-04-05 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
US20240050415A1 (en) 2020-06-05 2024-02-15 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
IL303965A (en) 2020-12-22 2023-08-01 Mekanistic Therapeutics Llc Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
WO2023016321A1 (zh) 2021-08-10 2023-02-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024228542A1 (ko) * 2023-05-04 2024-11-07 풍림무약주식회사 장용성 코팅용 조성물 및 이를 이용한 정제의 제조 방법
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4432996A (en) 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8512330D0 (en) 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
AU570853B2 (en) 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
CA2030581C (en) * 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
HUT74642A (en) * 1990-12-21 1997-01-28 Richardson Vicks Inc Polyamine drug-resin complex
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
ATE217188T1 (de) 1992-08-05 2002-05-15 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
EP1098635A1 (en) 2001-05-16
AU8898398A (en) 2000-02-07
RU2201217C2 (ru) 2003-03-27
ES2221188T3 (es) 2004-12-16
WO2000003696A1 (en) 2000-01-27
PL345774A1 (en) 2002-01-02
UA73092C2 (uk) 2005-06-15
CN1338925A (zh) 2002-03-06
BR9815948A (pt) 2001-02-28
DK1098635T3 (da) 2004-08-09
BG105203A (bg) 2001-09-28
ID27019A (id) 2001-02-22
NZ508298A (en) 2003-11-28
SK18832000A3 (sk) 2002-01-07
LV12638B (lv) 2001-09-20
HUP0102659A3 (en) 2002-12-28
CN1195499C (zh) 2005-04-06
US20020051818A1 (en) 2002-05-02
BG65443B1 (bg) 2008-08-29
EE200100033A (et) 2002-06-17
NO20010260D0 (no) 2001-01-16
DE69824319T2 (de) 2005-08-04
TR200003577T2 (tr) 2001-06-21
KR20010070981A (ko) 2001-07-28
NO330554B1 (no) 2011-05-16
LT2001003A (lt) 2001-06-25
HUP0102659A2 (hu) 2002-03-28
CZ2001215A3 (cs) 2001-10-17
JP2002520350A (ja) 2002-07-09
US6331316B1 (en) 2001-12-18
HU226492B1 (en) 2009-03-02
NO20010260L (no) 2001-03-07
PL195587B1 (pl) 2007-10-31
EE05021B1 (et) 2008-06-16
US6569457B2 (en) 2003-05-27
EP1098635B1 (en) 2004-06-02
GEP20032912B (en) 2003-03-25
DE69824319D1 (de) 2004-07-08
EG23944A (en) 2008-01-22
LT4844B (lt) 2001-09-25
EP1098635A4 (en) 2002-01-16
CA2337885A1 (en) 2000-01-27
KR100535954B1 (ko) 2005-12-12
CZ301557B6 (cs) 2010-04-14
ZA993446B (en) 2000-11-20
AR019934A1 (es) 2002-03-27
CA2337885C (en) 2008-01-08
PT1098635E (pt) 2004-09-30
LV12638A (lv) 2001-04-20
RO121082B1 (ro) 2006-12-29
SK285152B6 (sk) 2006-07-07
AU750388B2 (en) 2002-07-18
CO5090840A1 (es) 2001-10-30
ATE268165T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
HUP0102659A3 (en) Enteric coated pharmaceutical tablet and method of manufacturing
HUP0101714A3 (en) Enteric coated pharmaceutical composition and method of manufacturing
GB2345948B (en) Spiral formed products and method of manufacture
EP1242112A4 (en) PRODUCTS CONTAINING MEDICINANT SUBSTANCE PARTICLES AND PROCESS FOR PREPARING THE SAME
IL147304A0 (en) Interposer and method of making same
GB9929560D0 (en) Insert and method of manufacture thereof
PL326744A1 (en) Therapeutic sock and method of making same
AP2000001783A0 (en) Disinfectant and method of making
EP1024323A4 (en) CONNECTING POINT AND METHOD OF MANUFACTURING
EP0913496A4 (en) PART COATED BY HIGH-TEMPERATURE SPRAYING AND METHOD FOR THE PRODUCTION THEREOF
AP9701131A0 (en) Wall construction and method of manufacturing
GB9924334D0 (en) Pharmaceutical products and methods of fabrication therefor
HUP0003365A3 (en) Method of manufacturing sertindole and its intermediers
PL337785A1 (en) Lining unit and method of making same
PL340487A1 (en) Macaroni and method of making same
PL328680A1 (en) Container and method of manufacturing same
IL147758A0 (en) Integral capsule sourcewire and method of making
PL343396A1 (en) Latticework and method of making same
GB9814214D0 (en) Enteric coated pharmaceutical formulation
GB9720963D0 (en) Pharmaceutical compositions and method of production
GB2320901B (en) Targets and a method of manufacturing same
PL326434A1 (en) Pharmaceutical composition and method of manufacturing of the pharmaceutical composition
GB9915752D0 (en) Heatsink and method of manufacture
AUPO449597A0 (en) Therapeutic products and methods of manufacturing therapeutic products
PL307007A1 (en) Oral pharmaceutics form and method of obtaining same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired